A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer

Maria Q. Baggstrom; Yingwei Qi; Marianna Koczywas; Athanassios Argiris; Elizabeth A. Johnson; Michael J. Millward; Sara C. Murphy; Charles Erlichman; Charles M. Rudin; Ramaswamy Govindan

doi:10.1097/JTO.0b013e31822e2941

A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer

Maria Q. Baggstrom, Yingwei Qi, Marianna Koczywas, Athanassios Argiris, Elizabeth A. Johnson, Michael J. Millward, Sara C. Murphy, Charles Erlichman, Charles M. Rudin, Ramaswamy Govindan

School of Medicine

Research output: Contribution to journal › Article › peer-review

114 Scopus citations

Abstract

Background: AT-101 is an oral inhibitor of the antiapoptotic Bcl proteins (Bcl-2, Bcl-XL, Bcl-W, and Mcl-1) and an inducer of the pro-apoptotic proteins noxa and puma. We studied the efficacy of AT-101 in patients with recurrent chemosensitive extensive-stage small cell lung cancer (SCLC). Methods: Patients with recurrent "sensitive" SCLC (defined as no progression during and no disease recurrence

Original language	English (US)
Pages (from-to)	1757-1760
Number of pages	4
Journal	Journal of Thoracic Oncology
Volume	6
Issue number	10
DOIs	https://doi.org/10.1097/JTO.0b013e31822e2941
State	Published - Oct 2011

Keywords

AT-101
Extensive-stage small cell lung cancer
Gossypol

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine

Access to Document

10.1097/JTO.0b013e31822e2941

Cite this

@article{f72c929ca38749dcb64fc29e9949fb23,

title = "A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer",

abstract = "Background: AT-101 is an oral inhibitor of the antiapoptotic Bcl proteins (Bcl-2, Bcl-XL, Bcl-W, and Mcl-1) and an inducer of the pro-apoptotic proteins noxa and puma. We studied the efficacy of AT-101 in patients with recurrent chemosensitive extensive-stage small cell lung cancer (SCLC). Methods: Patients with recurrent {"}sensitive{"} SCLC (defined as no progression during and no disease recurrence ",

keywords = "AT-101, Extensive-stage small cell lung cancer, Gossypol",

author = "Baggstrom, {Maria Q.} and Yingwei Qi and Marianna Koczywas and Athanassios Argiris and Johnson, {Elizabeth A.} and Millward, {Michael J.} and Murphy, {Sara C.} and Charles Erlichman and Rudin, {Charles M.} and Ramaswamy Govindan",

year = "2011",

month = oct,

doi = "10.1097/JTO.0b013e31822e2941",

language = "English (US)",

volume = "6",

pages = "1757--1760",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "International Association for the Study of Lung Cancer",

number = "10",

}

TY - JOUR

T1 - A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer

AU - Baggstrom, Maria Q.

AU - Qi, Yingwei

AU - Koczywas, Marianna

AU - Argiris, Athanassios

AU - Johnson, Elizabeth A.

AU - Millward, Michael J.

AU - Murphy, Sara C.

AU - Erlichman, Charles

AU - Rudin, Charles M.

AU - Govindan, Ramaswamy

PY - 2011/10

Y1 - 2011/10

N2 - Background: AT-101 is an oral inhibitor of the antiapoptotic Bcl proteins (Bcl-2, Bcl-XL, Bcl-W, and Mcl-1) and an inducer of the pro-apoptotic proteins noxa and puma. We studied the efficacy of AT-101 in patients with recurrent chemosensitive extensive-stage small cell lung cancer (SCLC). Methods: Patients with recurrent "sensitive" SCLC (defined as no progression during and no disease recurrence

AB - Background: AT-101 is an oral inhibitor of the antiapoptotic Bcl proteins (Bcl-2, Bcl-XL, Bcl-W, and Mcl-1) and an inducer of the pro-apoptotic proteins noxa and puma. We studied the efficacy of AT-101 in patients with recurrent chemosensitive extensive-stage small cell lung cancer (SCLC). Methods: Patients with recurrent "sensitive" SCLC (defined as no progression during and no disease recurrence

KW - AT-101

KW - Extensive-stage small cell lung cancer

KW - Gossypol

UR - http://www.scopus.com/inward/record.url?scp=80052995730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052995730&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e31822e2941

DO - 10.1097/JTO.0b013e31822e2941

M3 - Article

C2 - 21918390

AN - SCOPUS:80052995730

SN - 1556-0864

VL - 6

SP - 1757

EP - 1760

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 10

ER -

A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this